Compare EZGO & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EZGO | SBFM |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.2M |
| IPO Year | 2020 | 2008 |
| Metric | EZGO | SBFM |
|---|---|---|
| Price | $0.77 | $2.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 58.7K | ★ 10.3M |
| Earning Date | 08-14-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,305,891.00 |
| Revenue This Year | N/A | $1.23 |
| Revenue Next Year | N/A | $22.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 4.11 |
| 52 Week Low | $0.01 | $0.13 |
| 52 Week High | $3.30 | $18.50 |
| Indicator | EZGO | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 77.69 |
| Support Level | $0.73 | $1.06 |
| Resistance Level | $1.28 | $3.05 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | -0.00 | 0.36 |
| Stochastic Oscillator | 27.52 | 85.86 |
EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.